Drug Discovery

AI concept image
#AI #Drug discovery #Novel therapeutics #Pharmaceutical industry #Software

Are claims of the success of AI in drug discovery backed by science? 

Optibrium, a developer of software and artificial intelligence (AI) solutions for drug discovery, recently announced the promotion of Dr Tamsin Mansley to President of its new subsidiary to lead its US-based team and business operations. DDW’s Megan Thomas spoke with Dr Mansley to learn more about what she considers… Read More

#Business & Investment #Exclusive Content #Opinion

Research scientist working in laboratory
#Cancer research #Drug discovery #Oncology #Pharma

Oncology Programme will accelerate cancer drug discovery

Biometrics contract research organisation (CRO) Phastar has joined Lean Life Science’s Oncology Development Programme (ODP2).   The targeted programme aims to identify and accelerate novel oncology innovations into commercially-attractive assets by offering support to academics and early-stage companies.  In collaboration with global pharma companies, Cancer Research… Read More

#Cancer Research #News

#Boehringer Ingelheim #Cancer research #Collaboration #Diabetes #Drug development #Drug discovery #Eli Lilly #HIV #Lung cancer #Neurodevelopmental disorders #Precision medicine #Rare disease

DDW Highlights podcast shares five new stories

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news.  ‘Teamwork makes the dream work’ this week, with the launch of… Read More

#News

#Biologics / Biotechnology #CAR-T #China #CRISPR #Drug discovery #Gene editing #Genetics / genomics #HIV #HPV #Oncology #Pharmacology #T cell activation #The Dose

The Dose: DDW’s drug discovery highlights

DDW highlights the most interesting global news and comments within the drug discovery and development sector this month.   Everyone enjoys a good news story and the drug discovery and development sector is no exception. Seeing tangible results of drug efficacy or therapeutics programmes can take years so it… Read More

#Exclusive Content

Human cells
#Biomarkers #Drug discovery #RNA sequencing #Single-cell RNA sequencing #Webinar

Event: Using native state cells to uncover true biological targets

Extensive manipulation, mechanical force and labelling methods used to enrich cells activate transcriptional programs that mask molecular profiles truly significant to any underlying disease. The consequence is the identification of drug targets that are not relevant to the biological process under study.  Camila Egidio Based on Nakhoda and Olszanski,… Read More

Webinar date:
Brought to you by LevitasBio
#News

San Diego
#Drug discovery #Drug Discovery Chemistry #Events

Programme announced for Drug Discovery Chemistry 2023

The 18th Annual Drug Discovery Chemistry meeting will be held on April 10-13, 2023 in San Diego, CA, US and also online.  Early bird registration closes on December 16.  Drug Discovery Chemistry is a conference for medicinal and biophysical chemists working in pharma, biotech, and… Read More

#News

#Boehringer Ingelheim #Cancer research #Collaboration #Diabetes #Drug development #Drug discovery #Eli Lilly #HIV #Lung cancer #Neurodevelopmental disorders #Precision medicine #Rare disease

This week in drug discovery (5-9 December)

News round-up for 5-9 December by DDW Digital Content Editor Diana Spencer. ‘Teamwork makes the dream work’ this week, with the launch of new partnerships to further the development of precision drugs in neurodevelopmental disorders, lung cancer and rare paediatric diseases. The benefits of collaboration have also been… Read More

#News

Amaranth oil
#Biopharmaceuticals #Drug discovery #Immunology / Virology & Vaccines #Plant-based

Plant-based squalene alternative suitable for vaccine use

Evonik has launched a non-animal-derived squalene suitable for vaccines and other pharmaceutical applications. PhytoSquene is the first known amaranth oil-derived squalene on the market for use in adjuvants in parenteral dosage forms. It is an alternative to animal-derived squalene, which for pharmaceutical applications is typically sourced from shark liver oil. Read More

#News

Human cells
#Biomarkers #Drug discovery #RNA sequencing #Single-cell RNA sequencing #Webinar

Why native state cells are needed to uncover true drug targets

Extensive manipulation, mechanical force and labelling methods used to enrich cells activate transcriptional programs that mask molecular profiles truly significant to any underlying disease. The consequence is the identification of drug targets that are not relevant to the biological process under study.  Camila Egidio Based on Nakhoda and Olszanski,… Read More

Webinar date:
Brought to you by LevitasBio
#News

#Drug development #Generics #Patent Law #Pharmaceuticals #Polymorphism #Small molecules

Polymorph profiling with X-ray powder diffraction protects patents and patients

By Dr Natalia Dadivanyan, Segment Marketing Manager, Malvern Panalytical  Small molecules can face big challenges  Despite the emergence of, and excitement around, advanced therapeutic modalities, traditional small molecule pharmaceuticals still occupy a significant and steadily growing share of the market. A recent report indicated… Read More

#Business & Investment #Exclusive Content

Elderly person with a cane
#Age-related diseases (ARDs) #Collagen #Drug discovery

Interest in collagen-related therapeutics grows as clinical trials increase

A new report reveals steadily growing interest in the clinical applications of collagen over the last 10 years.  Data analytics company Phesi analysed 2,358 clinical trials involving collagen. In the first 10 months of 2022, there were more than 225 new trials, compared with 125 in 2012. Dr Gen… Read More

#News

#Drug discovery #Gut microbiome #Sitting Down With

Exploring the microbiome: how it is shaping preclinical research

This is the latest DDW Sitting Down With sponsored podcast, which features Dr John Couse, Vice President of Scientific Services at Taconic Biosciences, who discusses how the microbiome is transforming drug discovery and what this means for pharmaceutical and biotech companies. Couse offers detailed insight into the microbiome and outlines its role… Read More

#Podcasts

#AI / data analytics / healthtech / informatics #Clinical trials #Covid-19 #Drug development #Healthcare #Public health #Regulatory

Drug development practices to improve public health policy 

Dr Andrew Garrett, Executive Vice President of Scientific Operations at ICON, explores the benefits of integrating some of the validation and standardisation practices already developed for PIs into the practices around NPIs and public health data; outlines some of the practices that can be implemented in order to do this;… Read More

#Exclusive Content #Opinion #Regulatory

#Drug discovery #Gut microbiome #Podcast

Listen to the new DDW Sitting Down With podcast episode

The latest DDW Sitting Down With sponsored podcast is now available. It features Dr John Couse, Vice President of Scientific Services at Taconic Biosciences, who discusses how the microbiome is transforming drug discovery and what this means for pharmaceutical and biotech companies. Couse offers detailed insight into the microbiome and… Read More

#News

#Cancer research #Covid-19 #Depression #Drug development #Drug discovery #FDA #Gene therapy #Malaria #Neuroscience #Olfactory disorders #Prostate cancer

Podcast: Keep up-to-date on the latest industry news

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news.  The industry has seen breakthroughs announced in malaria treatment, epilepsy and major… Read More

#News

Human cells
#Biomarkers #Drug discovery #RNA sequencing #Single-cell RNA sequencing #Webinar

Webinar: How single-cell RNA seq has advanced drug discovery

Extensive manipulation, mechanical force and labelling methods used to enrich cells activate transcriptional programs that mask molecular profiles truly significant to any underlying disease. The consequence is the identification of drug targets that are not relevant to the biological process under study.  Camila Egidio Based on Nakhoda and Olszanski,… Read More

Webinar date:
Brought to you by LevitasBio
#News